AI Summary Ocaliva (obeticholic acid) is a once-daily tablet for adults with primary biliary cholangitis who have an inadequate response to, or cannot tolerate, ursodeoxycholic acid.
Medically reviewed.
Obeticholic acid (Ocaliva) is a prescription tablet used to treat primary biliary cholangitis (PBC) in adults. Doctors consider it when ursodeoxycholic acid (ursodiol) has not worked well enough, or when a person cannot take ursodeoxycholic acid. Ocaliva is a farnesoid X receptor (FXR) agonist. It helps regulate how the liver makes and moves bile acids. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Ocaliva in PBC care: how it works, who may be eligible, how it is used, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Ocaliva fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT OCALIVA TREATMENT
Obeticholic acid is a prescription medicine sold under the brand name Ocaliva. It belongs to a class of medications called farnesoid X receptor (FXR) agonists. It helps regulate how the liver makes and transports bile acids.
Ocaliva treats primary biliary cholangitis (PBC), also called primary biliary cirrhosis. PBC is an autoimmune disease that damages the bile ducts in the liver. It affects more women than men and most often occurs between ages 30 and 60.
Ocaliva is not the first medicine most people with PBC receive. Ursodeoxycholic acid is the usual first-line treatment (see ursodiol). Ocaliva is a second-line option for adults who do not respond well enough to it or cannot tolerate it.
It is used with regular monitoring, such as Liver Function Tests (LFTs), to track how well it works.
WHO OCALIVA MAY BE SUITABLE FOR
Ocaliva is prescribed for adults with PBC who have an inadequate response to ursodeoxycholic acid, or who cannot tolerate it. Doctors usually check how well ursodeoxycholic acid is working about 12 months after you start it, using liver blood tests. If those tests stay abnormal, your provider may discuss a second-line option such as Ocaliva.
Ocaliva is not right for everyone. Its use is discouraged in people with decompensated liver disease (Child-Pugh class B or C). Your medical history, liver condition, and other medications all factor into the decision.
Because every patient's health profile is different, treatment decisions should be made by a qualified healthcare professional after a full assessment of your liver condition and treatment goals.
ELIGIBILITY OVERVIEW
Ocaliva may be considered for adults with the following conditions or treatment goals:
Before recommending Ocaliva, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW OCALIVA CAN HELP YOUR LIVER
Ocaliva activates farnesoid X receptors (FXR). These receptors help control how the liver makes bile acids and moves them out of liver cells. In PBC, bile does not flow normally, and bile acids build up and injure the liver.
By activating FXR, Ocaliva reduces bile acid production in the liver and improves bile flow. Less bile acid buildup means less liver inflammation. Liver enzyme levels linked to PBC can also improve.
For people with PBC, these effects support treatment goals such as better liver test results and a lower risk of the disease progressing. Ocaliva is not used alone in every case. Providers track response with regular monitoring, such as Liver Function Tests (LFTs).
LIVER BENEFITS
Ocaliva activates farnesoid X receptors (FXR) in the liver. These receptors help control how much bile acid the liver makes and how it moves bile acids out of liver cells. By reducing the amount of bile acid the liver produces, Ocaliva helps bring bile acid metabolism closer to normal.
When bile flows better, less bile acid stays trapped inside liver cells. Bile acids that build up can injure the liver, so improving bile flow helps lower the injury that drives PBC.
As bile acid buildup falls, liver inflammation tends to decrease. Less inflammation supports the treatment goal of lowering the risk of PBC progressing over time.
Ocaliva works directly on bile acid control in the liver to improve bile flow and ease inflammation in PBC. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Ocaliva is supplied as an oral tablet. Take it exactly as your healthcare provider prescribes, and ask your pharmacist if you have questions about your tablet.
The typical starting dose is 5 mg once daily. Your provider may increase it to 10 mg once daily based on how you respond and how well you tolerate it. Your healthcare provider sets the right dose for you.
Ocaliva is a once-daily tablet, not an injection or infusion. Take it with or without food, at the same time each day. Do not change your dose without medical guidance.
Ocaliva is intended as a long-term treatment for PBC. It is generally continued as long as it remains effective and well tolerated. Your provider will reassess regularly to confirm it is still safe and helpful. Do not stop taking it without talking to your provider first.
Store Ocaliva at room temperature, away from moisture and heat.
Your provider will regularly check liver function tests and your response to treatment. Follow-up for PBC usually includes liver tests every 3 to 6 months, plus other checks such as thyroid testing and bone density, depending on your situation. Report any side effects or unusual symptoms to your provider.
BENEFITS AND SAFETY
Ocaliva (obeticholic acid) may help people with PBC who have not responded well enough to ursodeoxycholic acid. It regulates bile acid production, improves bile flow, and can improve liver enzyme levels. How much it helps varies from person to person, depending on liver condition and how the body responds to therapy. Ocaliva works best as part of a broader care plan that includes healthy habits and ongoing monitoring, such as Liver Function Tests (LFTs).
As with any medication, Ocaliva may cause side effects. The most common are itching, fatigue, abdominal discomfort, joint pain, and dizziness. Your healthcare provider will monitor your treatment response throughout therapy and decide whether Ocaliva remains a suitable option for you.
BENEFITS
Ocaliva can improve markers of liver injury, including the liver enzyme levels linked to PBC. Your provider follows these levels with regular liver blood tests to see how you are responding.
A main goal of Ocaliva is to reduce the risk of PBC getting worse. Providers may discuss it when you need additional treatment to improve liver function.
Ocaliva is an option for adults who do not respond adequately to ursodiol or cannot tolerate it. Doctors usually check the response to ursodiol about 12 months after starting it, and may discuss Ocaliva if liver tests stay abnormal.
Ocaliva is a once-daily tablet, so it does not require injections or infusions. You can take it with or without food, at the same time each day. Your provider may adjust the dose based on your response and how well you tolerate it.
Tell your healthcare provider about any side effects. Your provider will discuss the potential benefits and risks before treatment and will keep monitoring your liver tests to support safe use.
SUPPORTING YOUR RESULTS
Lifestyle habits are an important part of PBC care alongside Ocaliva. A healthy diet, a healthy weight, no alcohol unless your provider directs otherwise, and steady medication use all support your liver.
These habits can support how your body responds to treatment. Regular follow-up visits let your provider check your liver tests and decide whether treatment is still working.
Areas that may support treatment:
Common questions
Ocaliva is prescribed for adults with primary biliary cholangitis (PBC) who have not responded well enough to ursodeoxycholic acid, or who cannot tolerate it. Doctors usually check how well ursodeoxycholic acid is working about 12 months after you start it, using liver blood tests. If those tests stay abnormal, your provider may discuss Ocaliva as a second-line option. Your provider will review your liver condition, medical history, and other medications before deciding.
Ursodeoxycholic acid (ursodiol) is the usual first-line treatment for PBC, while Ocaliva is a second-line option. Doctors usually check your response to ursodiol at about 12 months. Ocaliva may be discussed if liver tests stay abnormal or if you cannot tolerate ursodiol. Ocaliva is a farnesoid X receptor (FXR) agonist that regulates bile acid production and transport. Your provider can explain which option fits you.
Ocaliva is not right for everyone with advanced liver disease. Its use is discouraged in people with decompensated liver disease (Child-Pugh class B or C). Before recommending it, your provider reviews the stage and severity of your liver disease, including signs of decompensation, along with your medical history, current medications, and test results such as liver blood tests and imaging. Ask your healthcare professional whether Ocaliva fits your situation.
Take Ocaliva as a once-daily tablet, with or without food, at the same time each day. The typical starting dose is 5 mg once daily. Your provider may increase it to 10 mg once daily based on how you respond and how well you tolerate it. Do not change your dose without medical guidance. Your healthcare provider sets the right dose for you.
The most common side effects of Ocaliva are itching (pruritus), fatigue, abdominal discomfort, joint pain, and dizziness. Tell your healthcare provider about any side effects or unusual symptoms. Your provider will discuss the potential benefits and risks before treatment and keep monitoring your liver tests to support safe use. Do not stop the medicine on your own. Ask your provider what to expect and when to call.
Ocaliva is intended as a long-term treatment for PBC. It is generally continued as long as it remains effective and well tolerated. Your provider will reassess your treatment regularly, using liver function tests and follow-up visits, to confirm it is still safe and helpful. Do not stop taking Ocaliva without talking to your provider first. Ask what follow-up schedule makes sense for you.
No, Ocaliva does not cure PBC. PBC has no cure, but medicines can slow the disease and may help prevent complications. Ocaliva helps regulate bile acids, improve bile flow, and improve liver enzyme levels linked to PBC. How much it helps varies from person to person. Talk with your healthcare provider about realistic goals for your treatment plan.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
